ASSENT PLUS

Assessment of the Safety & Efficacy of a New Thrombolytic agent. A trial comparing dalteparin (TNKase™) to unfractionated heparin (UH) as an adjunct to rt-PA for improving coronary artery patency and outcome in patients with acute myocardial infarction (MI).
Conclusion Better blood flow with dalteparin than UH; no difference in acute MIs or death.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.